Pooled TENAYA, LUCERNE Phase 3 data reports safety, efficacy, lower treatment burden with faricimab for nAMD

The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability and safety of faricimab in patients with neovascular AMD.

Faricimab approved for treatment of nAMD, DMO by European Commission

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Fluid monitor utilises AI to identify, localise and quantify retinal fluid

Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.

Multicentre Phase 3 clinical trial using AI in nAMD identifies, measures fluid volumes in real time

September 06, 2022

According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.

Is retinal tissue preservation as important as decreased GA expansion in future therapies?

June 23, 2022

As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Dr Karl Csaky and Dr Fredrick Ferris III identified in 2007—Dr Csaky reinforces the importance of preserving the central retinal tissue.